IRIS
CARLOMAGNO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.750
EU - Europa 1.346
AS - Asia 1.054
SA - Sud America 68
AF - Africa 22
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.243
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.689
IT - Italia 627
SG - Singapore 531
CN - Cina 244
HK - Hong Kong 231
RU - Federazione Russa 151
FI - Finlandia 113
DE - Germania 110
UA - Ucraina 101
IE - Irlanda 92
BR - Brasile 62
CA - Canada 59
NL - Olanda 44
GB - Regno Unito 42
SE - Svezia 22
FR - Francia 20
IN - India 19
CI - Costa d'Avorio 18
IQ - Iraq 8
LT - Lituania 6
AT - Austria 4
PH - Filippine 4
ES - Italia 3
ZA - Sudafrica 3
AU - Australia 2
AZ - Azerbaigian 2
BE - Belgio 2
CL - Cile 2
IL - Israele 2
JP - Giappone 2
KR - Corea 2
PK - Pakistan 2
RO - Romania 2
VE - Venezuela 2
AL - Albania 1
AR - Argentina 1
BD - Bangladesh 1
BO - Bolivia 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EU - Europa 1
GR - Grecia 1
ID - Indonesia 1
JO - Giordania 1
KE - Kenya 1
LU - Lussemburgo 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PL - Polonia 1
SV - El Salvador 1
TR - Turchia 1
UZ - Uzbekistan 1
Totale 4.243
Salva come PNG Salva come JPEG
Città #
Singapore 278
Chandler 231
Hong Kong 225
Naples 161
Jacksonville 115
Santa Clara 103
Millbury 95
Princeton 92
Ashburn 80
Napoli 79
Nanjing 63
Ottawa 52
Boston 43
Wilmington 42
Amsterdam 36
Beijing 35
Nanchang 28
Woodbridge 25
Helsinki 21
The Dalles 20
Des Moines 19
Salerno 19
Shenyang 17
Augusta 16
Lawrence 15
Nocera Superiore 15
Hebei 14
Shanghai 14
Falls Church 13
Rome 13
Kronberg 12
Kunming 12
Munich 12
Ann Arbor 11
Boardman 11
Changsha 10
Waldbuttelbrunn 10
Giugliano in Campania 9
Seattle 9
São Paulo 9
Düsseldorf 8
New York 8
Nola 8
San Mateo 8
Washington 8
Acerra 7
Erbil 7
London 7
Milan 7
Redwood City 7
Santa Maria Capua Vetere 7
Tianjin 7
Toronto 7
Cantù 6
Falkenstein 6
Jiaxing 6
Norwalk 6
Nuremberg 6
Fisciano 5
Formia 5
Hangzhou 5
Indiana 5
Little Rock 5
Moscow 5
Tito 5
Cleveland 4
Dearborn 4
Ercolano 4
General Trias 4
Genoa 4
Hamburg 4
Portsmouth 4
Pozzuoli 4
Pune 4
Taranto 4
Afragola 3
Campinas 3
Casoria 3
Changchun 3
Chicago 3
Dallas 3
Dublin 3
Frankfurt am Main 3
Los Angeles 3
Pescara 3
Portoferraio 3
San Francisco 3
San Nicola 3
Serino 3
Sorrento 3
Araras 2
Bacoli 2
Baku 2
Barano d'Ischia 2
Bari 2
Battipaglia 2
Bloomsbury 2
Brussels 2
Buffalo 2
Caposele 2
Totale 2.350
Salva come PNG Salva come JPEG
Nome #
Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms 135
Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase 91
NCOA4 links iron bioavailability to DNA metabolism 86
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms 77
Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer 72
I geni oncosoppressori in "Patologia Generale" IV Ed, Pontieri-Russo-Frati 70
NCOA4 Deficiency Impairs Systemic Iron Homeostasis 66
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology 65
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes 63
Bioisosteric discovery of npa101.3, a second-generation ret/vegfr2 inhibitor optimized for single-agent polypharmacology 63
Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene. 62
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer 61
BAY 43-9006 inhibition of oncogenic RET mutants 60
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas 57
NCOA4 inhibits initiation of DNA replication to maintain genome stability 57
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases 57
Mechanisms of RET mediated signal transduction 55
BRAF is a therapeutic target in aggressive thyroid carcinoma. 55
Attacking cancer with molecularly targeted agents 55
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. 54
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases 53
NCOA4 transcriptional coactivator inhibits activation of DNA replication origins. 53
Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis 52
Activation of RET oncogene and thyroid carcinogenesis 50
NCOA4 Links Iron Bioavailability to DNA Metabolism 49
Ret gene fusions in malignancies of the thyroid and other tissues 49
Antitumor effects of ZD6474, a small molecule Vascular Endothelial Growth Factor receptor tyrosine kinase inhibitor, with additional activity against Epidermal Growth Factor. 47
Activation of RET as a dominant transforming gene by germline mutatios of MEN2A and MEN2B 47
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application 47
The Insulin Receptor Substrate (IRS)-1 recruits Phosphatidylinositol 3-Kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. 46
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas 46
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. 46
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affaected by familial medullary thyroid carcinoma. 46
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase 46
Central role of RET in thyroid cancer 46
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose 46
Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precursor protein: role of the low-density lipoprotein receptor-related protein. 45
Benzimidazole Analogues and related methods 45
POR Campania FESR SATIN 44
Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. 42
Basi molecolari delle nuove terapie: inibitori delle protein-chinasi. 42
Cloning of the rat tissue inhibitor of metalloproteinases type 2 (TIMP-2) gene: analysis of its expression in normal and transformed thyroid cells. 42
Receptor tyrosine kinases as targets for anticancer therapeutics 41
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma 41
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma 41
RET\PTC activation in human thyroid carcinomas 41
Different mutations of the RET gene cause different human tumoral diseases. 41
Constitutive and AP20187-induced ret activation in photoreceptors does not protect from light-induced damage 40
Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. 40
Molecular biology of the MEN2 gene 39
RET ONCOGENE ACTIVATION IN HUMAN THYROID NEOPLASMS IS RESTRICTED TO THE PAPILLARY CANCER SUBTYPE 38
Molecular Mechanism of RET in Human Cancer 38
Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation. 38
The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model 38
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. 35
Comparison of DNA repair protein expression and activities between human fibroblast cell lines with different radiosensitivities 34
The extent of linkage disequilibrium in four populations with distinct demographic histories 34
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. 34
Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy 34
POINT MUTATION OF THE RET PROTO-ONCOGENE IN THE TT HUMAN MEDULLARY THYROID CARCINOMA CELL LINE 33
Molecular targeting of the RET kinase in thyroid cancer 33
Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer 33
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). 32
Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells 32
Iron and ferritin modulate MHC Class i expression and NK cell recognition 32
The Macrophage Nuclear Receptor Coactivator 4 Counteracts Iron-Deficiency Anemia 32
Ret-mediated mitogenesis requires Src kinase activity 31
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase 30
Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease 30
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase 30
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. 30
Tamoxifen erythroid toxicity revealed by studying the role of nuclear receptor co-activator 4 in erythropoiesis 30
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation 30
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase. 29
Ret-mediated mitogenesis requires Src kinase activity. 29
Intracellular signaling by RET tyrosine Kynase 29
Signalling of the Ret receptor tyrosine kinase through the c-Jun N-terminal Protein Kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret 29
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) 29
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. 29
Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A 28
Molecular heterogeneity of RET loss of function in Hirschsprung's disease 28
Ret-mediated mitogenesis requires Src kinase activity 28
Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies. 28
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation 28
NCOA4-mediated ferritinophagy in macrophages is crucial to sustain erythropoiesis in mice 28
RET Is a Heat Shock Protein 90 (HSP90) Client Protein and Is Knocked Down upon HSP90 Pharmacological Block. 27
Evolutionary conservation of the Eps8 gene and its mapping to human-chromosome 12q23-q24 27
Receptor tyrosine kinase inhibitors in thyroid cancer. 26
Molecular Mechianism of RET Activation In Human Neoplasia 26
Molecular mechanisms of RET activation in human neoplasia. 26
Molecular mechanisms of RET activation in human cancer. 25
Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. 25
Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. 25
Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. 24
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival 24
Minireview:RET:normal and abnormal functions 23
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors 23
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474 23
Constitutive and AP20187-induced Ret activation in photoreceptors does not protect from light-induced damage. 23
The Human Eps15 gene encoding a tyrosine kinase substrate is conserved in evolution and map to 1p31-1p32 23
Totale 4.187
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.583
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.583
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020132 0 0 0 0 0 0 0 0 0 24 51 57
2020/2021317 10 33 27 33 22 48 28 13 23 3 67 10
2021/2022576 8 3 17 3 5 20 25 31 101 35 108 220
2022/2023623 117 45 5 52 76 64 10 53 89 56 41 15
2023/2024546 22 90 57 45 43 53 22 52 16 8 103 35
2024/20251.465 153 209 25 23 56 135 342 187 204 131 0 0
Totale 4.402